84 related articles for article (PubMed ID: 22286316)
1. Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes.
Park BW; Park S; Park HS; Koo JS; Yang WI; Lee JS; Hwang H; Kim SI; Lee KS
Breast Cancer Res Treat; 2012 Jun; 133(2):741-51. PubMed ID: 22286316
[TBL] [Abstract][Full Text] [Related]
2. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients.
Wiesner FG; Magener A; Fasching PA; Wesse J; Bani MR; Rauh C; Jud S; Schrauder M; Loehberg CR; Beckmann MW; Hartmann A; Lux MP
Breast; 2009 Apr; 18(2):135-41. PubMed ID: 19342238
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Denkert C; Winzer KJ; Müller BM; Weichert W; Pest S; Köbel M; Kristiansen G; Reles A; Siegert A; Guski H; Hauptmann S
Cancer; 2003 Jun; 97(12):2978-87. PubMed ID: 12784332
[TBL] [Abstract][Full Text] [Related]
5. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in Hungarian breast cancer patients.
Nádasi E; Anga B; Sándor J; Megyesi J; Kelemen D; Mottolese M; Natali PG; Hegedus G; Arany I; Ember I
Anticancer Res; 2007; 27(1A):279-82. PubMed ID: 17352244
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
Zhang XH; Huang DP; Guo GL; Chen GR; Zhang HX; Wan L; Chen SY
BMC Cancer; 2008 Jan; 8():4. PubMed ID: 18190720
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
Zerkowski MP; Camp RL; Burtness BA; Rimm DL; Chung GG
Cancer Invest; 2007 Feb; 25(1):19-26. PubMed ID: 17364553
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
[TBL] [Abstract][Full Text] [Related]
11. COX2 overexpression is a prognostic marker for Stage III breast cancer.
Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
[TBL] [Abstract][Full Text] [Related]
12. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay.
Potemski P; Pluciennik E; Bednarek AK; Kusinska R; Kubiak R; Jesionek-Kupnicka D; Watala C; Kordek R
Pathol Res Pract; 2006; 202(7):491-5. PubMed ID: 16678980
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ristimäki A; Sivula A; Lundin J; Lundin M; Salminen T; Haglund C; Joensuu H; Isola J
Cancer Res; 2002 Feb; 62(3):632-5. PubMed ID: 11830510
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer.
Matsubara N; Mukai H; Itoh K; Nagai S
Oncology; 2011; 81(5-6):345-52. PubMed ID: 22248824
[TBL] [Abstract][Full Text] [Related]
19. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
[TBL] [Abstract][Full Text] [Related]
20. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
